NCT04134273View on ClinicalTrials.gov

Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris

PHASE1CompletedINTERVENTIONAL
Enrollment

1,260

Participants

Timeline

Start Date

March 20, 2019

Primary Completion Date

September 17, 2019

Study Completion Date

October 15, 2019

Conditions
Acne Vulgaris
Interventions
DRUG

CLPG Topical Gel 1%

Clindamycin Phosphate Topical Gel 1% (Taro Pharmaceuticals U.S.A, Inc.)

DRUG

Clindamycin

Clindamycin Phosphate topical gel 1%

DRUG

Placebo

Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)

Trial Locations (1)

28217

Catawba Research, LLC, Charlotte

All Listed Sponsors
lead

Sun Pharmaceutical Industries, Inc.

INDUSTRY

NCT04134273 - Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris | Biotech Hunter | Biotech Hunter